Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 523

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 523
---
 delisting process with respect to our units and warrants, we expect that Nasdaq will file a Form 25 -NSEin respect of such securities with the SEC, and the delisting will become effective ten days after such Form 25 -NSEis filed. Although we expect that we will be notified by Nasdaq prior to the filing of such Form 25 -NSE, as well as prior to the release of a press release by Nasdaq announcing the delisting event, we are not at this time able to determine when such Form 25 -NSEwill be filed or when the delisting of our units and warrants from Nasdaq will be complete. However, the filing of the Form 25 -NSEby Nasdaq and the subsequent delisting of our units and warrants may occur at any time without prior notice. Despite the delisting of our securities from Nasdaq, we intend to proceed with our efforts to consummate our initial Business Combination. However, Nasdaq approval of OmnigenicsAI’s initial listing application with respect to the Business Combination is a condition to such Business Combination, and there can be no guarantee that Nasdaq will approve such initial listing application, which may delay, or ultimately prevent the consummation of the proposed Business Combination. Following the suspension of trading on Nasdaq, our Class A ordinary shares are quoted on the Pink Open Market of the OTC under the symbol “APXIF”. The Company will remain a reporting entity under the Securities Exchange Act of 1934, as amended, with respect to continued disclosure of financial and operational information. First and Second Extension On February 27, 2023, the Company held an extraordinary general meeting (the “February 2023 EGM”) and its shareholders approved an amendment to our amended and restated memorandum and articles of association (as amended, the “Articles of Association”) and to the investment management trust agreement dated as of September 7, 2021 (as amended, the “Trust Agreement”) to change the payment required to extend the Combination Period by two three -monthperiods (the “February Extension Amendment Amendment”). In connection with such vote, the holders of 10,693,417 public shares properly exercised their right to redeem their shares (and did not withdraw their redemption) for an aggregate redemption amount of $111,346,281. Following such redemptions, approximately $68,271,081 remained in the trust account and 6,556,583 public shares remained issued and outstanding. Such remaining amount in the trust account will be distributed either